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A sound knowledge base is required to target resources to reduce workplace exposure to carcinogens. This project aimed to provide
an objective estimate of the burden of cancer in Britain due to occupation. This volume presents extensive analyses for all carcinogens
and occupational circumstances defined as definite or probable human occupational carcinogens by the International Agency for
Research on Cancer. This article outlines the structure of the supplement – two methodological papers (statistical approach and
exposure assessment), eight papers presenting the cancer-specific results grouped by broad anatomical site, a paper giving industry
sector results and one discussing work-related cancer-prevention strategies. A brief summary of the methods and an overview of the
updated overall results are given in this introductory paper. A general discussion of the overall strengths and limitations of the study is
also presented. Overall, 8010 (5.3%) total cancer deaths in Britain and 13,598 cancer registrations were attributable to occupation in
2005 and 2004, respectively. The importance of cancer sites such as mesothelioma, sinonasal, lung, nasopharynx, breast, non-melanoma
skin cancer, bladder, oesophagus, soft tissue sarcoma and stomach cancers are highlighted, as are carcinogens such as asbestos,
mineral oils, solar radiation, silica, diesel engine exhaust, coal tars and pitches, dioxins, environmental tobacco smoke, radon,
tetrachloroethylene, arsenic and strong inorganic mists, as well as occupational circumstances such as shift work and occupation as
a painter or welder. The methods developed for this project are being adapted by other countries and extended to include social
and economic impact evaluation.
British Journal of Cancer (2012) 107, S3–S7; doi:10.1038/bjc.2012.112 www.bjcancer.com
& 2012 Cancer Research UK
Keywords: occupation; attributable fraction; deaths; registrations; burden of disease
                                                       
Doll and Peto (1981) estimated the proportion of cancer deaths in
Britain due to occupational causes as 4% (with an uncertainty
ranging from 2 to 8%), which equates to B6000 deaths per annum
(with a range of 3000–12000). The aim of this project was to
update the estimate of the burden of cancer in Britain due to
occupation. This involved estimating the current overall attribu-
table fractions (AF) and numbers of cancers due to occupation and
the relative contribution of occupational carcinogens and carcino-
genic processes. Evaluation was carried out for all carcinogenic
agents and occupations classified by the International Agency for
Research on Cancer (IARC) as a Group 1 (established) or 2A
(probable) human carcinogens, and for which evidence of
occupational exposure was either ‘strong’ or ‘suggestive’ for the
specific cancer site (Siemiatycki et al, 2004; Rousseau et al, 2005;
Straif et al, 2005; Straif et al, 2007).
The summary results from this project have been published
previously in the BJC (Rushton et al, 2010), and this supplement
provides more detail about the methodology, data and results for
each cancer site. Complete technical reports covering these topics
will be available on the Health and Safety Executive (HSE) website
(http://www.hse.gov.uk/cancer/). The aim of this study has been to
develop appropriate practical measures to reduce health risks to
workers arising from exposure to carcinogens in the workplace.
Identifying the number of workers exposed occupationally to
carcinogens and the circumstances of these exposures are also key
aspects of this study and are described in the methodology and
exposure assessment papers in this supplement. The need for a
sound baseline of evidence to inform future decision making by
regulators is discussed in the final paper.
STRUCTURE OF THE SUPPLEMENT
A brief summary of the methods and an overview of the updated
overall results are given in this introductory paper together with a
discussion of the overall strengths and limitations of the study.
Two papers in this volume provide details of the methodology
developed specifically for the project, a statistical methods paper
followed by a paper describing the sources of available exposure
data for the different carcinogens and the process of allocation of
industry sectors to different levels of exposure. The cancer-specific
results are presented in eight papers grouped by broad anatomical
site; each paper gives a brief overview of the incidence, trends,
occupational and non-occupational risk factors associated with the
specific cancer, an overview of the literature reviewed for each carci-
nogen and the process of selection of appropriate data for burden
estimation. One of the unique aspects of this study is the identification
of occupations and industry sectors to target for risk reduction.
Brief results were presented in our overview paper (Rushton et al,
2010). More detailed results for industry sectors highlighting the
important ones defined by large numbers, multiple carcinogens
and/or cancer sites are given in a separate paper in this *Correspondence: Dr L Rushton; E-mail: l.rushton@imperial.ac.uk
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tion strategies and how predictive science may help address the
burden of occupational cancer in the twenty-first century.
METHODOLOGY
The primary measure of the burden of cancer used in this project
was the AF, that is, the proportion of cases that would not have
occurred in the absence of exposure; this was then used to estimate
the attributable numbers (ANs; see Hutchings and Rushton
(2012a), for more detailed statistical methods). The AF requires
the risk of the disease due to the exposure of interest and the
proportion of the target population exposed. Risk estimates,
adjusted where appropriate for confounders, were obtained from
key studies, meta-analyses or pooled studies, taking into account
study quality. Dose–response risk estimates were generally not
available in the epidemiological literature, nor were proportions of
those exposed at different levels of exposure over time available for
the working population in GB. However, where possible, risk
estimates were obtained for an overall ‘lower’ level and an overall
‘higher’ level of exposure to the agents of concern and matched
appropriately to the exposure scenario in question. The risk
estimates used in the study are given in the overview technical
report on the HSE website (HSE, 2012).
The period during which exposure occurred, which was relevant
to the development of the cancer in the target year 2005, was
defined as the risk exposure period (REP). For solid tumours, a
latency of 10–50 years was assumed, giving a REP of 1956–1995;
for haematopoietic neoplasms, a latency of 0–20 years was
assumed, giving a REP of 1986–2005. The proportion of the
population ever exposed to each carcinogenic agent or occupation
in the REP was obtained from the ratio of the number of people
ever exposed to the carcinogens of interest in each relevant
industry/occupation within GB over the total number of people
ever employed. National data were used to obtain these (see Van
Tongeren et al (2012) for a more detailed account of the exposure
aspects). Account was taken of changes in the number of people
employed in the primary and manufacturing industry and service
sectors in GB over the REP where appropriate, and adjustment
was made for employment turnover over the period. Given the
assumptions made about cancer latency and working age range,
only cancers in patients aged 25 years and above in 2005/2004
could be attributable to occupation for the REP for long latency
cancers, as well as cancers occuring in an age group of 15–79 for
women and 15–85 for men for the REP for short latency cancers.
National data sources such as the CARcinogen EXposure database
(CAREX; Pannett et al, 1998), the UK Labour Force Survey (LFS,
2009) and Census of Employment (ONS, 2009) were used to
estimate the number of people ever exposed over the REP.
OVERVIEW OF RESULTS
During the interval between publication of the overall results (Rushton
et al, 2010) and production of this supplement, some minor
corrections were made to several cancer site/exposure estimations.
Table 1 therefore presents the updated results for the AFs and ANs,
and Table 2 gives the number of cancer registrations by cancer site
and ranked by carcinogen or occupational circumstance. The overall
burden by cancer site (AFs, ANs and 95% confidence intervals) is
given in Table 1. In all, 8.2% (n¼6355) of cancer deaths in 2005 in
men and 2.3% (n¼1655) in women in Britain have been estimated to
be due to occupation, giving an overall AF of 5.3% (n¼8010). The
combined AFs for registrations are 5.7% (n¼9988) for men in 2004
and 2.1% (n¼3611) for women, giving an overall AF based on
registrations of 4.0% (n¼13,598). The AFs are similar to those
published before, but there are nine fewer deaths and the number of
registrations is reduced by 81 (75 of which are in men; see footnotes in
Table 2 for the reasons estimates that have changed). The changes
occurred mainly in non-melanoma skin cancer due to exposure to
polycyclic aromatic hydrocarbons (PAH) in coal tars and pitches
where the update now excludes glaziers in the job category ‘roofers
and glaziers’, which were included in error in the earlier estimation.
However, these amended results have not changed the conclu-
sions from our previous publication. The most important cancer
sites for occupational attribution are mesothelioma, sinonasal,
lung and bladder cancers and non-melanoma skin cancer for men,
and mesothelioma, sinonasal, lung, breast and nasopharyngeal
cancers for women (Table 1). The agents responsible for most
occupation-attributable cancers, each with over 100 attributable
cancer registrations, are asbestos, shift work, mineral oils, solar
radiation, silica, diesel engine exhaust, PAHs from coal tar and
pitches, dioxins, environmental tobacco smoke encountered at
work in non-smokers, radon exposure from natural exposure in
workplaces, tetrachloroethylene, arsenic and strong inorganic acid
mists, as well as occupation as a painter or a welder (Table 2).
DISCUSSION
Our estimate of the current burden in 2005 of occupation-related
cancers of 5.3% translates to over 8000 cancer deaths in GB and is
in contrast to the 212 deaths due to occupational injuries that
occurred in 2005/06 (HSE, 2006). Burden estimates from other
studies range between 3 and 10%, partly due to differences in the
numbers of cancers and carcinogens considered. The study has
identified several industry sectors and occupations with high
numbers of attributable cancer deaths and registrations including
construction, metal working, personal/household services, mining,
land transport, printing/publishing, retail/hotels/restaurants, pub-
lic administration/defence, farming and several manufacturing
sectors (Hutchings and Rushton, 2012b). The construction
industry and agriculture and farming together contributed 43%
of the fatal injuries reported in 2005/06 (HSE, 2006), and our study
adds to the work-related concerns in these industries, both of
which also have the potential for increased risks from substances
associated with respiratory diseases (Rushton, 2007).
The results presented in this supplement must be considered
taking into account several uncertainties and limitations. Agents
classified by IARC by the end of 2008 as Group I and 2A carcinogens
were assessed. Other substances, such as IARC group 2B carcinogens,
many of which may be treated as if they were human carcinogens in
regulatory settings, have not yet been evaluated; our estimates could
thus be too low. In addition, our estimates do not include evaluation
of the results from the review and update by IARC of all Group 1
carcinogens carried out in 2009, in which a separate classification
(potentially varying) was given for all cancer sites that were relevant
to specific carcinogens. Our estimates are thus almost certainly an
underestimate of the true burden.
The assumptions made in the methodology used for this study
may have introduced uncertainty or bias in the estimates. For
example, studies of British workforces were not always available
from which to choose appropriate risk estimates; the study chosen
may not have reflected exposures experienced in GB; and there may
have been differences in distributions of confounders. However, it
should be noted that the majority of risk estimates were obtained
from meta-analyses, pooled studies or reviews. There was a paucity
of available information on risk estimates for women, and for many
carcinogens the risk estimates for men were used for women. In
addition, most estimates were for mortality rather than for
incidence. Epidemiological studies of occupational groups are often
confounded by a ‘healthy worker effect’, that is, a reduced overall
risk estimate compared with the general population. This, together
with potential misclassification of exposure in epidemiological
studies, could lead to an underestimation of the true effect and thus
an underestimation of the burden.
Occupational cancer in Britain
S4
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Cancer site Attributable fraction (%) Attributable numbers
(95% confidence interval) (95% confidence interval)
ICD-10 Deaths (2005)
a Registrations (2004)
code Male Female Total Male Female Total Male Female Total
Bladder C67 7.1
(4.6, 9.7)
1.9
(1.3, 3.9)
5.3
(3.4, 7.7)
215
(139, 296)
30
(21, 62)
245
(159, 358)
496
(321, 684)
54
(37, 110)
550
(357, 795)
Bone C40–C41 0.04 0.01 0.02 0 0 0 0 0 0
Brain C70–C72 0.5
(0.1, 1.1)
0.1
(0, 0.2)
0.3
(0.0, 0.7)
10
(1, 20)
1
(0, 3)
11
(1, 23)
12
(1, 25)
2
(0, 4)
14
(1, 28)
Breast C50 4.6
(3.3, 6.0)
4.6
(3.3, 6.0)
555
(397, 727)
555
(397, 727)
1969
(1407, 2579)
1969
(1407, 2579)
Cervix C53 0.7
(0.0, 2.1)
0.7
(0.0, 2.1)
7
(0, 22)
7
(0, 22)
18
(1, 56)
18
(1, 56)
Kidney C64–C66,
C68
0.04
(0, 0.16)
0.04
(0, 0.14)
0.04
(0, 0.15)
1
(0, 3)
1
(0, 2)
1
(0, 5)
2
(0, 7)
1
(0, 4)
3
(0, 10)
Larynx C32 2.9
(1.4, 5.7)
1.6
(0.6, 3.5)
2.6
(1.2, 5.2)
17
(8, 34)
3
(1, 6)
20
(9, 40)
50
(24, 99)
6
(2, 13)
56
(26, 112)
Leukaemiaa C91–C95 0.9
(0.2, 3.5)
0.5
(0.1, 4.5)
0.7
(0.1, 4.5)
18
(4, 71)
5
(1, 49)
23
(5, 120)
30
(7, 118)
9
(1, 80)
38
(8, 198)
Liver C22 0.2
(0.1, 0.3)
0.1
(0.1, 0.2)
0.2
(0.1, 0.3)
4
(2, 6)
2
(1, 2)
5
(3, 8)
4
(2, 6)
1
(1, 2)
5
(3, 8)
Lung C33–C34 21.1
(19.2, 24.7)
5.3
(4.3, 6.9)
14.5
(13.0, 17.2)
4020
(3659, 4696)
725
(592, 946)
4745
(4251, 5643)
4627
(4212, 5406)
815
(666, 1063)
5442
(4877, 6469)
LH C81–C96 0.004
(0, 0.014)
0.002
(0, 0.007)
0.003
(0, 0.011)
0
(0, 1)
0
(0, 0)
0
(0, 1)
0
(0, 1)
0
(0, 0)
1
(0, 2)
Melanoma (eye) C69 2.9
(0.6, 6.6)
0.4
(0.1, 1.0)
1.6
(0.3, 3.6)
1
(0, 3)
0
(0, 0)
1
(0, 3)
6
(1, 13)
1
(0, 2)
6
(1, 15)
Mesothelioma C45 97.0
(96.0, 98.0)b
82.5
(75.0, 90.0)b
94.9
(93.0, 96.9)b
1699
(1681, 1717)
238
(216, 260)
1937
(1898, 1976)
1699
(1681, 1717)
c 238
(216, 260)
c 1937
(1898, 1976)
c
MM C90 0.4
(0, 1.0)
0.1
(0, 0.3)
0.3
(0, 0.7)
5
(0, 10)
1
(0, 2)
6
(0, 12)
8
(0, 18)
2
(0, 3)
10
(0, 21)
Nasopharynx C11 10.8
(2.3, 47.9)
2.4
(0.6, 6.8)
8.0
(1.8, 34.3)
7
(2, 31)
1
(0, 2)
8
(2, 33)
14
(3, 61)
1
(0, 4)
15
(3, 65)
NHL C82–C85 2.1
(0, 6.9)
1.1
(0.1, 2.9)
1.7
(0, 5.4)
43
(0, 138)
14
(1, 37)
57
(1, 176)
102
(0, 328)
39
(3, 101)
140
(3, 430)
NMSCd C44 6.9
(1.3, 15.0)
1.1
(0.0, 2.9)
4.5
(0.8, 9.9)
20
(4, 44)
2
(0, 6)
23
(4, 50)
2513
(478, 5447)
349
(0, 899)
2862
(478, 6346)
Oesophagus C15 3.3
(1.5, 7.5)
1.1
(0.3, 2.8)
2.5
(1.1, 5.9)
156
(70, 358)
28
(8, 70)
184
(78, 429)
159
(71, 365)
29
(9, 74)
188
(80, 439)
Ovary C56 0.5
(0, 1.2)
0.5
(0, 1.2)
23
(0, 52)
23
(0, 52)
33
(0, 76)
33
(0, 76)
Pancreas C25 0.02
(0, 0.07)
0.01
(0, 0.04)
0.01
(0, 0.05)
1
(0, 2)
0
(0, 1)
1
(0, 4)
1
(0, 2)
0
(0, 1)
1
(0, 4)
Sinonasal C30–C31 43.3
(27.3, 74.0)
19.8
(14.4, 31.6)
32.7
(21.5, 54.8)
27
(17, 47)
10
(8, 16)
38
(25, 63)
95
(60, 162)
31
(23, 50)
126
(83, 212)
STS C49 3.4
(0, 11.4)
1.1
(0, 3.8)
2.4
(0, 8.1)
11
(0, 36)
3
(0, 9)
13
(0, 45)
22
(0, 75)
4
(0, 15)
27
(0, 90)
Stomach C16 3.0
(1.5, 5.1)
0.3
(0.1, 0.5)
1.9
(1.0, 3.4)
101
(52, 176)
6
(3, 11)
108
(55, 187)
149
(77, 258)
9
(4, 15)
157
(81, 274)
Thyroid C73 0.12 0.02 0.05 0 0 0 0 0 1
Total: C00–C97
Based on
deaths
8.2
(7.2, 9.9)
2.3
(1.7, 3.2)
5.3
(4.6, 6.6)
6355
(5640, 7690)
1655
(1249, 2287)
8010
(6888, 9977)
Based on
registrations
5.7
(4.0, 8.4)
2.1
(1.4, 3.2)
4.0
(2.7, 5.9)
9988
(6938, 14,794)
3611
(2370, 5412)
13,598
(9308, 20,206)
Total cancers in
GB in ages 15þ
77,912 72,212 150,124 175,399 168,184 343,583
Abbreviations: GB¼Great Britain; ICD¼International Classification of Diseases; NHL¼non-Hodgkin’s lymphoma; NMSC¼non-melanoma skin cancer;
STS¼soft-tissue sarcoma.
aAttributable fraction applicable to all leukaemias.
bIncludes cases described as due to paraoccupational or environmental exposure to asbestos.
cTaken
as equal to attributable deaths for this short survival cancer.
dBased on registrations. Confidence intervals (CIs) were not estimated for bone and thyroid cancers, and other cancers
attributed to ionising radiation, as CI estimates are not yet available for the excess relative risk models used (refer UNSCEAR report).
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Cancer sitea
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Total attributable
cancer
registrationsb
Asbestos 8 2223 1937 47 4216
Shift work (including flight personnel) 1957 1957
Mineral oils 296 470 902 55
d 1730
Solar radiation 1541 1541
Silica 907 907
Diesel engine exhaust 106 695 801
PAHs: coal tars and pitches 475
e 475
Painters 71 282 83 359
TCDD (dioxins) 215 74 27 316
Environmental tobacco
smoke (non-smokers)
284 284
Radon 209 209
Welders 175 175
Tetrachloroethylene 18 17 130 164
Arsenic 129 129
Strong inorganic-acid
mists containing sulphuric acid
46 76 122
Chromium VI 67 22 89
Non-arsenical insecticides 11 19 33 MM (10) 73
Cobalt 73 73
Inorganic lead
f
24 2 2 3 6 7
Aromatic amines 66 66
Hairdressers and barbers 15 14 33 63
Soots 60 60
Wood dust 14 39 54
Leather dust 31 31
Steel foundry workers 29 29
Formaldehyde
g
10 1 1 12
Cadmium 9 9
Rubber industry 36 9
Nickel
h
90 9
PAHs 71
i 8
Beryllium 7 7
Trichloroethylene 3 Kidney (3)
Liver (2)
7
Benzene 7 7
UV radiation
(welders only)
Melanoma-
eye (6)
6
Ionising radiation
12
Bone (0)
Liver (0)
Thyroid (1) 4
Vinyl chloride Liver (3) 3
1,3-Butadiene 0 LH (1) 1
Acrylamide Pancreas (1) 1
Tin miners
j 1 1
Ethylene oxide 1 1
Petroleum refining 0 0
Total registrations attributable
to occupation
550 14 1969 18 56 38 5442 1937 15 2862 140 188 33 126 27 157 26 13,598
Total cancer registrations
in GB (2004)k
9878 3933 43,202 2612 2112 5202 37,378 2037 189 67,220 8236 7488 6197 378 1063 7970 22,034
l 339,156
m
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‘low’ exposure and allocating suitable risk estimates was a response
to the lack of data on proportions exposed at different levels of
exposure and the fact that many studies of occupational groups use
relatively simple approaches to exposure assessment, for example,
job titles. For most of the carcinogens considered, risk estimates
in the source studies were related to some estimate of cumulative
exposure. In assigning ‘higher’ and ‘lower’ categories to the industry
groups for the calculation of the proportions exposed, e.g., using
CAREX, implicit assumptions were made regarding the similarity
of durations and intensities of exposure between the source and
target (national) populations. Where no risk estimate could be
identified for low levels of exposure, we estimated a relative risk
(RR) based on harmonic mean of the high/low ratios across all other
cancer–exposure pairs in the overall project where data were
available; if the resulting RR estimate was o1, RR was set to 1. This
may have led to inaccurate risk estimates for the low categories
(either too large or too small). A substantial proportion of the ANs
is likely to have resulted from a large number of workers with low
exposures.
Our figures could have underestimated the number of workers
‘ever exposed’ in the REP because workers with o1y e a ro f
employment were not included in the analysis consistent with the
exclusion of short term workers in many occupational epidemiolo-
gical studies. Inclusion of these would have increased the numbers
ever exposed considerably and hence increase the AFs and numbers.
There is a general paucity of information on latency of cancers
due to occupational carcinogens, and hence we made pragmatic
assumptions about the length of the latency period and hence the
REP. This resulted in high estimates in some situations.
Work is ongoing to explore the sensitivity of the estimates to the
sources of uncertainty and bias discussed above. An important
aspect throughout this project was the involvement of interna-
tional experts, including IARC, in advising on the methodology
and interpretation of the results and peer reviewing the many
technical reports. This supplement, together with the detailed
technical reports on the HSE website, facilitates the transparent
presentation of the methodology, data and results from this
project. These methods have the potential to be adapted for use in
other countries and extended to include social and economic
impact evaluation. For example, the methodology and results
contained in this study are informing an on-going estimation of
occupational cancer for the Global Burden of Disease programme
undertaken by the World Health Organisation.
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Abbreviations: GB¼Great Britain; LH¼lymphohaematopoietic malignancies; MM¼multiple myeloma; NHL¼non-Hodgkin’s lymphoma; NMSC¼non-melanoma skin cancer;
PAH¼polycyclic aromatic hydrocarbon; STS¼soft-tissue sarcoma; TCDD¼2,3,7,8-tetrachlorodibenzodioxin; UV¼ultraviolet.
aBlank cells indicate that attributable cancer
registrations were not estimated for this occupational exposure. Zero represents an estimate of o0.5.
bTotals by cancer site are based on the product sums of the separate
estimates of attributable fraction for each agent, and are not therefore equal to the sums of the separate estimates of attributable registrations for each agent. The difference is
especially notable where the constituent attributable fractions and therefore attributable numbers are large.
cRubber industry now excluded from stomach cancer estimation to
avoid double counting.
dPrinters and the dermally exposed industries now excluded from the sinonasal estimates for mineral oils.
eGlaziers now excluded from job group ‘roofers
and glaziers’.
fPrinting industry now classified as low exposure rather than high.
gWood product industry now classified as low exposure rather than high.
hCorrections made to the
numbers exposed to nickel in the high exposed Clydach cohort.
iCorrections made to the estimates for PAHs.
jCorrections made to the numbers exposed in tin
mining.
kRegistrations aged 25 years and above for solid tumours, and ages 15–84 for men, and 15–79 for women, for haematopoietic neoplasms. Figures for mesothelioma are
based on deaths.
lIncludes bone, kidney, liver, melanoma (eye), MM, pancreas and thyroid.
mAll malignant neoplasms, ages 25 years and above (ICD 10th revision C00–C80) and
15–84/79 (ICD 10th revision C80–C97).
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